Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.25    0.50 (3.57%)
Bid:
14.00
Ask:
14.50
Spread: 0.50 (3.571%)
Market Cap: £11.97m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Elute Intelligence appoints Steve Cable as CEO

14 Oct 2022 07:00

RNS Number : 8774C
Frontier IP Group plc
14 October 2022
 

REACH

AIM: FIPP

14 October 2022

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Elute Intelligence appoints Steve Cable as Chief Executive Officer

 

Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company Elute Intelligence Holdings Limited ("Elute" or the "Company") has appointed Steve Cable as Chief Executive Officer. Steve will guide the organisation through the development of existing Elute products with an emphasis on product alignment, market traction and commercial growth.

 

Steve has more than 25 years' experience in building businesses at start-ups, mid-size firms and large companies. He has worked with software solutions in Artificial Intelligence, Search, Professional Services Automation, Enterprise Resource Planning, and Identity Management across a wide diversity of sectors.

 

His experience of leading strategy, positioning solutions, and penetrating existing markets, is a core requirement for Elute. This was recently demonstrated where he was part of leadership team at CMap Software. The Company went from being a relatively unknown start up to industry leader with more than £4m annual recurring revenues, leading to a private equity investment in December 2019.

 

The Elute technology is based on encoding forensic linguistic principles in software. The core competency enables documents to be read in a manner similar to humans, but by a computer at great speed. It is possible for the system to 'read' millions of documents in seconds and identify the documents that are of greatest relevance. The software can clearly show the user why documents are relevant, a marked difference to artificial intelligence or semantic search approaches used by competing products.

 

Other complementary competencies allow rapid detailed comparison of text in documents, authorship detection for plagiarism and collusion detection, and an ability to automatically summarise documents. While Elute's current products are English language based, the functionality is not language dependent and therefore the products could in principle be applied to a wide range of languages including English, Russian, Arabic and Chinese.

 

The technology is live, proven, and trusted by organisations such as UCAS and the Open University.

 

Steve Cable, Elute Chief Executive Officer, said: "I joined Elute due to the many possible applications of the technology. I've had the benefit of working in two of the UK's leading SaaS search software providers, so I immediately recognised the possibilities. In the short time I've been on board we have made big strides and we expect to be able to launch a new differentiated product very soon. My primary aim is taking this technology to market, gaining user feedback, and monetising as soon as possible." 

 

Frontier IP Chief Executive Neil Crabb said: "Elute has the potential to transform the way in which we search and compare text stored in large, complex, and unstructured datasets. We are very pleased that Steve has been appointed Elute's Chief Executive. He has already made great progress since he joined the Company, and we are looking forward to working with him as CEO as he takes it forward to success."

 

ENQUIRIES

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / George Payne

 

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

This is a RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFEDDEESESS
Date   Source Headline
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20197:00 amRNSBoard Appointment
27th Mar 20197:00 amRNSUnaudited Half Year Results
21st Mar 20199:18 amRNSTrading Update
21st Mar 20199:14 amRNSExscientia & Celgene drug discovery collaboration
6th Mar 20195:15 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSTVG - key partner in $9.67m DARPA project award
12th Feb 20197:00 amRNSThird Portuguese spin out: Insignals Neurotech
4th Feb 20197:00 amRNSAmprologix wins DHSC backing for new antibiotic
31st Jan 20199:00 amRNSNandi Proteins led consortium wins UK grant
25th Jan 20197:00 amRNSThe Vaccine Group wins Department of Health grant
7th Jan 20191:29 pmRNSExscientia Series B funding & Roche collaboration
27th Dec 20187:00 amRNSMolendotech - Palintest start commercial roll out
19th Dec 201811:45 amRNSResult of AGM
30th Nov 20185:30 pmRNSTotal Voting Rights
23rd Nov 201812:10 pmRNSPosting of Annual Report and Notice of AGM
22nd Nov 20181:12 pmRNSHolding(s) in Company
22nd Nov 201810:36 amRNSHolding(s) in Company
21st Nov 20183:30 pmRNSHolding(s) in Company
21st Nov 201811:00 amRNSTotal Voting Rights and Director/PDMR Shareholding
15th Nov 20184:08 pmRNSDirector Dealing
15th Nov 201812:37 pmRNSGrant of Options
15th Nov 201810:05 amRNSExscientia acquires Kinetic Discovery
15th Nov 20189:30 amRNSPlacing to raise £2.49 million
15th Nov 20189:25 amRNSFinal Results
30th Oct 20187:00 amRNSSecond Portuguese spin out: Des Solutio
19th Oct 20187:00 amRNSMolendotech signs collaboration agreement with G's
5th Oct 20187:00 amRNSDIT hails Frontier IP's Portuguese success
27th Sep 20187:00 amRNSChange of Adviser
26th Sep 20185:12 pmRNSDirector Declaration
24th Sep 20182:30 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSAmprologix to develop new antibiotics with Ingenza
18th Sep 20181:56 pmRNSAlusid raises £1.34m to scale up manufacturing
17th Sep 20187:00 amRNSAB Sugar Head of Innovation joins Frontier IP
30th Aug 201812:39 pmRNSHolding(s) in Company
15th Aug 20187:00 amRNSTVG awarded £50,000 anti-bacterial vaccine grant
7th Aug 20187:00 amRNSPortfolio news - first Portuguese spin out
6th Aug 20187:00 amRNSFieldwork Robotics agreement with Hall Hunter
2nd Aug 20187:00 amRNSFrontier IP partners with UK DIT in Portugal
16th Jul 20187:00 amRNSTarsis Collaboration with Crop-Protection Company
11th Jul 20187:00 amRNSInnovate UK grant for Pulsiv Solar
19th Jun 20187:00 amRNSCambridge Material Testing Solutions
15th May 20187:00 amRNSPalintest launches Molendotech bathing water test
18th Apr 20184:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSIncreased Equity Holding in Fieldwork Robotics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.